BioLife Solutions, Inc. (BLFS) financial statements (2021 and earlier)
Company profile
| Business Address |
3303 MONTE VILLA PARKWAY BOTHELL, WA 98021 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 3845 - Electromedical and Electrotherapeutic Apparatus (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 21 | 20 | 32 | 31 | 32 | 14 | 7 | ||
| Cash and cash equivalents | 21 | 20 | 32 | 31 | 32 | 14 | 7 | ||
| Receivables | 4 | 4 | 3 | 3 | 3 | 2 | 1 | ||
| Inventory, net of allowances, customer advances and progress billings | 6 | 5 | 4 | 4 | 3 | 2 | 2 | ||
| Inventory | 6 | 5 | 4 | 4 | 3 | 2 | 2 | ||
| Other undisclosed current assets | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total current assets: | 32 | 29 | 39 | 38 | 38 | 19 | 10 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1 | 1 | 1 | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Long-term investments and receivables | 1 | 6 | 6 | 7 | 7 | 2 | 1 | ||
| Long-term investments | 1 | 6 | 6 | 7 | 7 | 2 | 1 | ||
| Intangible assets, net (including goodwill) | 45 | 14 | |||||||
| Goodwill | 28 | 10 | |||||||
| Intangible assets, net (excluding goodwill) | 16 | 4 | |||||||
| Deposits noncurrent assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed noncurrent assets | 3 | ||||||||
| Total noncurrent assets: | 52 | 23 | 9 | 8 | 8 | 3 | 2 | ||
| TOTAL ASSETS: | 84 | 52 | 48 | 45 | 46 | 22 | 12 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 4 | 2 | 2 | 2 | 2 | 2 | 1 | ||
| Accounts payable | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Accrued liabilities | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Employee-related liabilities | 2 | 1 | 1 | 1 | 1 | 1 | 0 | ||
| Debt | 1 | 1 | 1 | ||||||
| Deferred rent credit | 0 | 0 | 0 | 0 | |||||
| Business combination, contingent consideration, liability | 0 | 0 | |||||||
| Total current liabilities: | 5 | 3 | 3 | 2 | 2 | 2 | 1 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1 | 1 | 1 | ||||||
| Finance lease, liability | 0 | 0 | 0 | ✕ | ✕ | ✕ | ✕ | ||
| Operating lease, liability | 1 | 1 | 1 | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 2 | 2 | 0 | 0 | 0 | 0 | 1 | ||
| Deferred rent credit | 0 | 0 | 0 | 0 | |||||
| Other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Business combination, contingent consideration, liability | 2 | 2 | |||||||
| Total noncurrent liabilities: | 2 | 2 | 1 | 0 | 0 | 0 | 1 | ||
| Total liabilities: | 7 | 5 | 4 | 2 | 3 | 2 | 2 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 77 | 46 | 44 | 43 | 44 | 20 | 10 | ||
| Preferred stock | 0 | 0 | 0 | ||||||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 137 | 116 | 115 | 114 | 116 | 93 | 85 | ||
| Accumulated deficit | (60) | (70) | (71) | (71) | (72) | (73) | (74) | ||
| Total stockholders' equity: | 77 | 46 | 44 | 43 | 44 | 20 | 10 | ||
| TOTAL LIABILITIES AND EQUITY: | 84 | 52 | 48 | 45 | 46 | 22 | 12 | ||
Income statement (P&L) ($ in millions)
| 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 7 | 7 | 6 | 5 | 5 | 5 | 4 | |
| Cost of revenue (Cost of Goods and Services Sold) | (2) | (2) | (2) | (2) | (2) | (2) | (1) | |
| Gross profit: | 5 | 5 | 4 | 4 | 4 | 4 | 2 | |
| Operating expenses | (5) | (4) | (4) | (3) | (2) | (2) | (2) | |
| Operating income (loss): | (1) | 1 | 0 | 1 | 1 | 1 | 0 | |
| Nonoperating income (expense) | 10 | (0) | (0) | (0) | 0 | (0) | (0) | |
| Interest and debt expense | (0) | (0) | (0) | (0) | (0) | (0) | (0) | |
| Income from continuing operations before equity method investments, income taxes: | 9 | 1 | 0 | 1 | 1 | 1 | 0 | |
| Loss from equity method investments | (1) | |||||||
| Other undisclosed income from continuing operations before income taxes | 0 | 0 | 1 | 0 | 0 | |||
| Net income: | 9 | 1 | 0 | 1 | 1 | 1 | 0 | |
| Other undisclosed net income attributable to parent | 0 | 0 | ||||||
| Net income attributable to parent: | 9 | 1 | 0 | 1 | 1 | 1 | 0 | |
| Preferred stock dividends and other adjustments | (0) | (0) | (0) | (0) | ||||
| Net income (loss) available to common stockholders, diluted: | 9 | 1 | 0 | 1 | 1 | 1 | (0) | |
Comprehensive Income ($ in millions)
| 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income: | 9 | 1 | 0 | 1 | 1 | 1 | 0 | |
| Comprehensive income, net of tax, attributable to parent: | 9 | 1 | 0 | 1 | 1 | 1 | 0 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.